Product Description
Mechanisms of Action: RvE1 Antagonist
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Topical,Ophthalmic
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: C.T. Development America
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
![Map of Global Clinical Trials for Navamepent](https://pryzm-maps.s3.us-west-2.amazonaws.com/666666current_maps.png)
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Inflammation|Cataract|Conjunctivitis, Allergic|Dry Eye Syndromes|Dry Eye Disease|Keratoconjunctivitis Sicca
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
ATR-45-1401 | P2 |
Completed |
Cataract|Inflammation |
2015-09-01 |
|
CTD1201 | P2 |
Completed |
Dry Eye Syndromes|Dry Eye Disease|Keratoconjunctivitis Sicca |
2012-11-01 |
|
CTD1202 | P2 |
Completed |
Conjunctivitis, Allergic |
2012-08-01 |
|
NCT00799552 | P2 |
Completed |
Keratoconjunctivitis Sicca|Dry Eye Syndromes |
2009-05-01 |